Mucormicosis diseminada
ICD-10 B46.4 · ICD-11 1F2C.1
Tratamiento de la Mucormicosis Diseminada con Afectación del Sistema Nervioso Central (Cerebro)
Escenario Clínico
Este protocolo cubre la mucormicosis diseminada que se presenta con afectación del sistema nervioso central (cerebro) — una manifestación grave que requiere un manejo inmediato y estructurado para limitar la progresión de la enfermedad.
Objetivos del Tratamiento
El objetivo es alcanzar una enfermedad estable o una respuesta parcial, con resolución de los signos y síntomas de infección y mejora radiológica sustancial, evaluada mediante imágenes programadas de forma regular.
References
- In CNS involvement, animal models and the above observations support use of liposomal amphotericin B at 10 mg/kg per day.
- The guideline group strongly supports an early complete surgical treatment for mucormycosis whenever possible, in addition to systemic antifungal treatment.
- Doses should not be slowly increased over several days; rather, the full daily dose should be given from the first treatment day.
- When switching to oral treatment, use of isavuconazole or posaconazole delayed release tablets is strongly supported.
- In view of the rapid progress of mucormycosis, weekly CT scans are strongly recommended, particularly in unstable patients.
- Therapy can be continued until resolution of signs and symptoms of infection, and substantial radiographical improvement.